Epidemiological and Clinical Profile of Mpox Diagnosed at the National Laboratory of Clinical Biology of Public Health in Bangui, Central African Republic

Résumé fourni par la source

Introduction: Monkeypox (MPXV) epidemics historically result from the zoonotic spread of clade I monkeypox virus (MPXV) in Central Africa and clade II MPXV in West Africa. In 2022, subclade IIb caused a global epidemic linked to sexual transmission. It is in this context that this study was conducted to determine the prevalence of MPXV at the Bangui National Laboratory. Methodology: This was a prospective, multicenter analytical study. Skin, blood, and oropharyngeal swabs were collected from suspected MPXV patients. A total of 50 samples were recorded during this study. Diagnosis was performed using real-time PCR. The study received approval from the Research Ethics Committee of the Doctoral School of Human and Veterinary Health Sciences, University of Bangui (ESP/CE/78/2024). Participants gave verbal consent for data collection. Results: The mean age of patients was 29.20 years with a standard deviation of ±19.07 and the median age of individuals was 25.50 years with a male predominance of 22.73%. Out of 50 patients suspected of Mpox, 30% of patients had muscle pain followed by intense fever with lymphadenopathy and 20% were confirmed positive by polymerase chain reaction. The most dominant age group was between 11 and 20 years with a rate of 0.30% of positive cases for Mpox. The difference in patients infected with Mpox is not significant with a p ≤ 0.70 and the male gender is the most dominant with a rate of 22.73% of cases of positivity to Mpox with a p-value of 0.46. Conclusion: This study shows that molecular diagnostics identified mutations characteristic of clade I, with a strong signal of APOBEC3 mutation pressure, suggesting active human-to-human transmission in CAR. Enhanced surveillance and an early diagnostic strategy would be necessary to eradicate the Mpox epidemic in CAR.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.